>>> Zealand Pharma: New data from Phase 2 ZUPREME-1 trial further supports poten

Zealand Pharma: New data from Phase 2 ZUPREME-1 trial further supports potential of petrelintide to redefine the weight management experience
  • Co announces the presentation of additional data from its Phase 2 ZUPREME-1 trial, evaluating investigational petrelintide, at the 2026 Scientific Sessions of the American Diabetes Association® (ADA).
  • Results from the 42-week, Phase 2 trial show that participants who received once-weekly subcutaneous injections of petrelintide, an amylin analog, achieved clinically meaningful reductions in body weight compared to placebo.
  • Treatment with petrelintide was associated with improvements in cardiometabolic disease risk factors and was well tolerated with rates of gastrointestinal (GI)-related adverse events (AEs) generally similar to placebo.
    • Clinically meaningful, double-digit weight loss demonstrated through week 42.
    • Placebo-like tolerability observed and low rates of treatment discontinuation due to gastrointestinal adverse events.
    • Treatment associated with improvements in cardiometabolic disease risk factors, including reductions in waist circumference, high-sensitivity C-reactive protein and triglycerides.
    • Data reinforces the potential of petrelintide to enhance treatment persistence and address current challenges of treatment durability, tolerability and acceptability.
    • Phase 3 trials for chronic weight management planned for initiation in 2H26.

>>> NOVOB : Phase 2 zenagamtide trial meets A1C and body weight endpoints in typ

Phase 2 zenagamtide trial meets A1C and body weight endpoints in type 2 diabetes
- In 262 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor, once-weekly subcutaneous zenagamtide met the primary endpoint of change in A1C across all doses versus placebo after 36 weeks and the key supportive secondary endpoint of body weight change with doses 1.5 mg and greater.
- At 40 mg, zenagamtide cut A1C by up to 1.71 percentage points from a 7.8% baseline, with up to 89.1% achieving A1C below 7% and up to 76.2% at or below 6.5%.
- Zenagamtide also reduced body weight by up to 14.6% at week 36 with the 40 mg dose. Novo Nordisk plans to initiate a phase 3 development program in H2 2026.

FT : Meta weighs big equity raising after blockbuster Google deal

Meta weighs big equity raising after blockbuster Google deal
Facebook parent could sell tens of billions of dollars in new stock as it seeks to finance AI infrastructure

Meta is considering raising tens of billions of dollars in a stock offering as it seeks new sources of capital to fund Mark Zuckerberg’s vast ambitions in AI, following the launch of Google’s record $85bn share deal this week.

Executives at the social media company have been exploring “creative” ways to raise cash as it prepares to sharply boost its AI-related capital expenditures to as much as $145bn this year and even higher in 2027, according to three people familiar with the plans.

After the success of Google parent Alphabet’s equity raising this week, which was increased by $5bn after strong investor demand, the discussions have intensified, the people said. 

Meta shares were down about 7 per cent in US trading on Friday before closing down 5.5 per cent, with the decline having accelerated following the FT’s report over its talks about an equity fundraising.

Meta’s discussions over a fresh share sale come amid a frenzy of activity in US equity capital markets, with Elon Musk’s SpaceX set to hold its initial public offering next week and AI groups Anthropic and OpenAI also working on plans for massive Wall Street debuts.

Big Tech companies have also tapped debt markets as they rush to finance AI infrastructure, including chips and data centres.

Finance chief Susan Li is leading the talks over the potential share sale alongside Dina Powell McCormick, who moved from Meta’s board to take a more active role as president in January.

Powell McCormick has been tasked with overhauling Meta’s approach to AI infrastructure and financing, with a focus on longer-term planning as it enters the most capital-intensive period in its history.

Meta must find new ways to fund the huge data centres needed to train and run advanced AI models to fulfil Zuckerberg’s vision for “personal superintelligence” delivered through Facebook, WhatsApp and Instagram, as well as a family of AI-powered wearables such as smart-glasses and voice pendants.

Meta has not yet hired banks and ultimately may not issue new stock. One person cautioned that it was “premature” to say that the company had decided what to do and all financing options remain on the table.

A Meta spokesperson said the share sales talks were “pure speculation”, but added “we’ve been clear that huge opportunities lie ahead in AI, and we’ll continue focusing on raising capital in the most flexible ways to support that”.

A person familiar with Meta’s discussions said the group had looked at the structure of Alphabet’s capital raising, which included “mandatory convertible preferred issuance”. This allows it to raise cash immediately, but defers the stock issuance potentially for years.

Goldman Sachs would be in a strong position to win the Meta mandate considering Powell McCormick spent 16 years at the investment bank. The Wall Street bank led the Google deal announced this week.

Meta executives are conscious that they will have to move fast if they decide to raise equity to ensure capacity and investor enthusiasm remain amid a historic glut of activity in US public markets.

SpaceX is set to raise as much as $86bn next week in an IPO that would value the group at $1.78tn. Claude maker Anthropic has confidentially filed for its own listing and rival OpenAI is also preparing to go public. Both are expected to raise tens of billions and attract $1tn-plus valuations.

Analysts say that Meta’s Big Tech rivals such as Microsoft and Amazon are also likely to be considering their own stock sales as their data centre spending surges and investors question the impact on their balance sheets.

Meta has already raised fresh capital through new means and innovative structures.

The company had less than $10bn in long-term debt as recently as 2022, but borrowed $55bn in globe-trotting deals in recent months. In October, it raised $27bn in a bond sale through a joint venture with private capital firm Blue Owl to build a Manhattan-sized data centre in Louisiana dubbed “Hyperion”.

Meta has also been conserving capital by cutting costs and other means. Last month it fired 8,000 people and stopped hiring for 6,000 roles.The company also halted share buybacks in late 2025 after repurchasing its shares regularly since 2017.

Google paused its buyback programme in the first quarter after repurchasing about $45bn last year, according to FactSet data and company filings.

FT : SpaceX signs $30bn deal to lease computing capacity to Google

SpaceX signs $30bn deal to lease computing capacity to Google
Agreement comes ahead of a record-breaking initial public offering for Elon Musk’s rockets-to-AI conglomerate

SpaceX has signed a $920mn-a-month deal to lease computing capacity to Google, as Elon Musk’s rockets-to-AI conglomerate races to boost revenue ahead of a record-breaking initial public offering next week.

SpaceX on Friday disclosed the agreement in a Securities and Exchange Commission filing, which said the deal would be worth more than $30bn over the length of the contract. It follows an arrangement similar to one it inked with Anthropic, as Musk puts SpaceX’s role as an AI powerhouse at the centre of its future ambitions.

The two deals combined will contribute more than $26bn to SpaceX’s annual revenue, boosting the company’s financial performance as it seeks an unprecedented $1.8tn valuation in next week’s listing.

But they also signal that Musk’s own Grok chatbot is lagging behind competitors. Google, Anthropic and OpenAI have been hunting for computing capacity to meet increasing demand for their tools.

Earlier this week Google announced a record $85bn equity raise to fund its massive AI infrastructure spending.

The SpaceX-Google deal is the latest in a fast-growing web of tie-ups linking chipmakers, data centre operators and AI model-builders as Big Tech races to bring computing power online to satisfy surging AI demand.

Google Cloud said the two companies were “longtime partners” and said it was “a short-term, timely agreement to ensure we have bridge capacity to meet surging customer demand” for its AI models.

SpaceX has pinned AI as its largest market with research analysts at Goldman Sachs this week projecting revenues from the division would surge 100-fold to $322bn by 2030.

Revenues of that scale would only be achievable if Musk can either create a leading AI model that captures what he estimates to be a $26.5tn market for the technology or if SpaceX becomes the dominant provider of AI infrastructure.

The billionaire’s ultimate ambition is to harness the power of the sun to power “orbital data centres” — satellite-based computing clusters. In a pitch to investors hosted by JPMorgan’s chief executive Jamie Dimon on Thursday, Musk said putting AI data centres in space would not be a “particularly difficult thing to do, and in fact easier than our communication satellites”.

“We do intend with our SpaceX AI satellites to allow people to put whatever [graphics processing units] or [central processing units] they want [on them],” Musk said, adding the rocket maker would someday send up 1 terawatt of “space compute” from Earth and 1,000 times that from a future manufacturing base on the Moon.

SpaceX said in its SEC filing that the contract with Google includes access to 110,000 Nvidia GPUs and the other components and would be worth roughly $11bn per year until June 2029, though it could be cancelled by either side earlier.

SpaceX’s computing capacity deals with Anthropic include access to 325,000 Nvidia GPUs at its Colossus facilities in Tennessee.